Valneva's IXCHIQ shows 94% seroresponse five years after single dose
VALN•Valneva reported five-year study results showing a 94% seroresponse after one dose of its chikungunya vaccine IXCHIQ.
1. Five-year immune response
Valneva reported sustained antibody responses five years after a single dose of its chikungunya vaccine IXCHIQ. Older adults showed antibody persistence comparable to younger adults, and participants will be followed for up to 10 years to assess the durability of immune responses.
